Choose a language and wait for the translated text.
Shots:
Innogen Pharmaceuticals has entered into an exclusive licensing & commercialization agreement with Arcera Life Sciences, granting Arcera rights to efsubaglutide alfa in selected countries in Africa, Latin America, the Middle East & Eastern Europe, while Innogen retains rights in the RoW
Innogen will receive $38M in upfront & near-term milestones, incl. a non-refundable upfront payment of $15M, plus sales milestones & tiered royalties of up to double-digit percentage on net sales; the total potential deal value is over $1B
Efsubaglutide alfa, a GLP-1 analogue-IgG Fc fusion protein approved for T2D in mainland China & Macao, showed 10.6% avg. body-weight reduction with 20mg QW for 18wks. in the P-IIb (ENLIGHT) study in Chinese adults with overweight or obesity
Ref: PR Newswire | Image: Innogen Pharmaceuticals | Arcera Life Sciences | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Innogen Pharmaceuticals Enters into an Exclusive Licensing Agreement with Arcera Life Sciences for Efsubaglutide Alfa appeared first on PharmaShots.